Equities

ALK-Abello A/S

ALK-Abello A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)159.60
  • Today's Change-2.10 / -1.30%
  • Shares traded67.01k
  • 1 Year change+101.01%
  • Beta1.0972
Data delayed at least 15 minutes, as of Nov 05 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

  • Revenue in DKK (TTM)5.18bn
  • Net income in DKK690.00m
  • Incorporated1961
  • Employees2.81k
  • Location
    ALK-Abello A/SBoege Alle 6-8HOERSHOLM 2970DenmarkDNK
  • Phone+45 45747576
  • Fax+45 45748690
  • Websitehttps://www.alk.net/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALK B:CPH since
announced
Transaction
value
AllerQuest LLC-PRE-PENDeal completed02 Jan 202402 Jan 2024Deal completed57.71%--
Data delayed at least 15 minutes, as of Nov 05 2024 16:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioGaia AB866.75m215.35m6.75bn222.0032.516.7725.897.793.333.3313.4216.010.6442----6,455,538.0016.0015.4717.7316.9373.5973.3024.8527.70----0.00104.4217.4411.81-2.2511.2029.2728.10
Bonesupport Holding AB520.73m57.91m13.87bn131.00241.8933.22214.5326.631.361.3612.299.921.160.61385.627,756,762.0012.85-9.0814.98-11.2892.4390.2511.12-11.653.50--0.0222--79.7643.65459.44--18.39--
Vimian Group AB2.63bn1.91m14.81bn1.10k8,924.753.0057.945.640.0050.0058.3714.890.34012.856.753,733,535.000.0938--0.1025--46.88--0.2758--2.182.060.2734--17.92--245.95------
Bavarian Nordic A/S6.08bn707.42m16.88bn1.38k23.641.6012.942.779.069.0678.44133.680.41571.505.104,410,899.004.831.216.241.4856.9153.7211.634.060.9311--0.01180.00124.1469.78524.66--35.76--
Camurus AB1.02bn142.74m22.47bn228.00157.5311.96147.6122.053.793.7927.5149.940.61221.094.867,480,770.008.58-1.1310.10-1.4192.0190.0514.01-1.637.11--0.0071--79.52103.39676.63--16.29--
ALK-Abello A/S5.18bn690.00m32.76bn2.81k52.297.2832.956.323.093.0922.9122.220.76731.276.111,834,278.0010.223.5012.564.3763.4260.6613.325.071.29479.500.09340.006.9410.6045.07--16.32--
Orion Oyj10.66bn2.47bn47.43bn3.82k19.136.8516.254.452.362.3610.166.580.95931.536.94393,502.2022.2519.4728.2524.1659.8959.3823.1920.711.41143.690.217491.83-11.264.01-37.971.8911.821.55
Swedish Orphan Biovitrum AB (publ)16.26bn2.25bn76.30bn1.81k33.333.1016.584.6910.0610.0672.98108.010.34431.375.7214,353,840.004.755.935.857.6078.6077.4213.8116.610.62254.350.3250.0017.7419.34-8.68-0.072953.61--
Data as of Nov 05 2024. Currency figures normalised to ALK-Abello A/S's reporting currency: Danish Krone DKK

Institutional shareholders

17.05%Per cent of shares held by top holders
HolderShares% Held
ATP Arbejdsmarkedets Till�gspensionas of 31 Dec 202311.23m5.54%
The Vanguard Group, Inc.as of 02 Oct 20244.73m2.34%
M&G Investment Management Ltd.as of 30 Sep 20244.45m2.20%
Norges Bank Investment Managementas of 30 Jun 20243.22m1.59%
Dimensional Fund Advisors LPas of 03 Oct 20242.18m1.08%
BlackRock Fund Advisorsas of 03 Oct 20241.93m0.95%
BI Asset Management Fondsm�glerselskab A/Sas of 31 Aug 20241.83m0.90%
Danske Bank A/S (Investment Management)as of 31 Aug 20241.78m0.88%
Financi�re de l'�chiquier SAas of 31 Mar 20241.78m0.88%
Artisan Partners LPas of 30 Sep 20241.40m0.69%
More ▼
Data from 31 May 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.